Latest news with #CRDMO
Yahoo
6 days ago
- Business
- Yahoo
Expansion of Frontage Laboratories Continues with Launch of New State-of-the-Art CRDMO Facility in Exton, PA
EXTON, Pa., June 2, 2025 /PRNewswire/ -- Frontage Laboratories, Inc. officially unveiled its newest Contract Research, Development and Manufacturing Organization (CRDMO) facility during a grand open house event held on May 22, 2025, at its campus in Exton, Pennsylvania. The event marked the official launch of 46,300-square-foot Good Manufacturing Practice (GMP) facility located at 240 Sierra Drive. This expansion enhances Frontage's CRDMO footprint and reinforces its commitment to accelerating pharmaceutical and biotech innovation. This facility includes nine (9) GMP suites: two (2) high-potent suites, two (2) aseptic suites, and five (5) non-sterile suites, supporting manufacturing for injectables, tablets, capsules, creams, gels, ointments, ophthalmic and nasal preparations. This building also houses two (2) formulation development labs, and three (3) analytical labs including a micro lab. It provides a comprehensive, one-stop-shop solution for pharmaceutical and biotech clients covering all aspects of clinical supplies, including formulation development, manufacturing, analytical testing, packaging, labelling, distribution, and storage. This expansion complements Frontage's existing service offerings, which include drug substance synthesis, DMPK, safety & toxicology studies, bioanalysis, and clinical trial support. "We are grateful to all who joined us to share in our joyous occasion. The grand opening of this new CRDMO marks a significant milestone for us in the CDMO and clinical trial material supply space," said Dr. Song Li, Founder and Executive Chairman of Frontage. Dr. Wentao Zhang, Co-CEO of Frontage Laboratories, added, "For years, Frontage has been expanding by opening new sites and acquiring existing ones. The launch of our new state-of-the-art CDMO facility significantly enhances our manufacturing capabilities, positioning us closer to our clients and enabling us to respond more efficiently to their evolving development and supply needs." About Frontage Frontage Laboratories, Inc., a wholly owned subsidiary of Frontage Holdings Corporation (HKEX: is a US based global CRDMO offering end-to-end integrated product development services from drug discovery through late-phase clinical trials and manufacturing. With over 25 years of experience, Frontage supports pharmaceutical and biotech companies with services including drug discovery, API synthesis, DMPK, safety and toxicology, formulation development, GMP manufacturing, analytical services, clinical trials, bioanalytical services and central lab operations. Frontage operates 26 sites worldwide and has played a pivotal role in helping clients secure regulatory approvals across the US, Canada, Europe, and Asia. For more information, visit or email info@ Media Contact:Xiaoyun Niuxniu@ 232-0100 View original content to download multimedia: SOURCE Frontage Laboratories, Inc.
Business Standard
16-05-2025
- Business
- Business Standard
Jubilant Pharmova jumps after reporting turnaround Q4 performance
Jubilant Pharmova rallied 4.54% to Rs 947.05 after the company reported net profit of Rs 153.60 crore in Q4 FY25 compared with net loss of Rs 58.60 crore in Q4 FY24. Revenue from operations increased 9.7% YoY to Rs 1,915.80 crore in Q4 FY25. The company reported pre-tax profit of Rs 206 crore in Q4 FY25 as against pre-tax loss of Rs 53.70 crore in Q4 FY24. EBITDA jumped 23% to Rs 357 crore during the quarter compared with Rs 289 crore in Q4 FY24. EBITDA margin expanded 210 bps to 18.4% in Q4 FY25 as against 16.3% in Q4 FY24. In Q4 FY25, radiopharmaceuticals revenue grew by 15% YoY to Rs 296 crore, while revenue from radio pharmacy increased 7% YoY to Rs 600 crore in Q4 FY25. Revenue from Allergy Immunotherapy rose 2% YoY to Rs 192 crore and CDMO sterile injectables grew by 31% YoY to Rs 340 crore during the quarter . Contract research, development and manufacturing organisation (CRDMO) revenue stood at Rs 338 crore in Q4 FY25, up 19.86% YoY. The generics business reported revenue of Rs 157 crore in Q4 FY25, reflecting a 22% YoY decline. On full year basis, the companys consolidated net profit surged 988.7% to Rs 839.40 crore on 8.2% increase in revenue from operations to Rs 7,192.10 crore in FY25 over FY24. On the outlook front, in the Radiopharmaceuticals business, the company expects continued growth in Ruby-Fill installations. It remains on track to launch multiple new products in PET and SPECT imaging between FY27 and FY29. The dosing for the Phase 2 clinical trial of MIBG has been completed, and the data package is being prepared for submission to the US FDA by the second half of FY26. On the therapeutic front, over 10 new products are expected to be commercially available starting in 2029, supporting the expansion of the PET imaging industry. The proposed investment in six radiopharmacies is progressing, with commercial operations expected to begin from FY28 onwards. In the Allergy Immunotherapy segment, the company, as the sole supplier of Venom in the US, is working to expand the market by enhancing customer awareness. Revenue continues to grow in the US allergenic extracts business, and efforts are underway to penetrate markets beyond the US. In the CDMO Sterile Injectables segment, the capacity expansion at the Spokane, Washington facility is on schedule. Line 3 and Line 4 are expected to commence commercial production in late FY26 and FY28, respectively. Peak utilisation for Line 3 is now anticipated within three years of commercial launch, ahead of the earlier estimate of four years. In the CRDMO business, the medium-term outlook continues to be positive. In the short term, the business is trying to diversify its customer base and for the medium term, it is adding development capabilities in addition to research and manufacturing. In the CDMO API segment, efforts are concentrated on improving capacity utilisation through CDMO projects and custom generics manufacturing. In the Generics business, the company plans to launch six to eight products per annum in across US and non-US international markets. Export volumes to the US are being scaled up gradually and meaningfully, with increased contributions expected from contract manufacturing partners. The business aims to enhance profitability and return to growth in FY26. In the Proprietary Novel Drugs segment, interim data from the Phase 2 trial of JBI-802 is anticipated in FY26. Shyam. S. Bhartia, chairman Jubilant Pharmova and Hari S Bhartia, co-chairman & non-executive director, said, We are pleased to announce revenue of Rs 7,235 crore in FY25, growth of 8% over last year. We delivered robust revenue growth across Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables and CRDMO businesses. EBITDA grew by 24% to Rs 1,230 crore on the back of strong operating performance across all business units. EBITDA margins for the year expanded by 220 basis points. Reported PAT grew by 1,050% to Rs 836 crore, while normalised PAT grew by 112% to Rs 415 crore on the back of improved operating performance and reduced finance cost. Net Debt / EBITDA reduced from 2.5x in Mar24 to 1.1x in Mar25 on the back of voluntary debt prepayment of USD 125 million in FY25. In Feb2025, we outlined our Vision 2030, which is to double our revenues from FY24 to FY30, improve EBITDA margins to 23% to 25% range, reduce Net debt to zero and grow Return on Capital to high teens. Our FY25 financial performance takes us one-step closer to our Vision. During the year, the company started distributing Pylarify, an industry leading prostate cancer diagnostic imaging agent from PET radiopharmacies, completed Media Fills on Line 3 in CDMO Sterile Injectables, added strategic capabilities in the area of Biologics and Antibody drug conjugates in Drug Discovery, reached profitability in the Generics business and dosed first patients in JBI-802 and JBI-778 clinical trials. The large innovator pharma companies, for their US requirements, are now looking to create an alternate manufacturing site in the US as a risk management measure in the event of tariff imposed by the US govt. Therefore, the company is starting to see excellent traction in the CDMO Sterile Injectable business for new lines in the Spokane facility. We expect to reach peak utilisation for Line 3 in 3 years from start of commercial production vs 4 years, expected earlier." Meanwhile, the companys board recommended a final dividend of Rs 5 per share of Re 1 each for FY25. The dividend, if approved by the shareholders, will be paid within 30 days from the date of the Annual General Meeting. The company has fixed the record date as Friday, 25 July 2025, for the purpose of final dividend payment. Jubilant Pharmova is a globally present company engaged in radiopharmaceuticals, allergy immunotherapy, CDMO sterile injectables, contract research, development and manufacturing (CRDMO), generics, and proprietary novel drugs businesses.
Yahoo
15-05-2025
- Business
- Yahoo
STEERLife Redefines Potent Drug Development with Clean, Green, Continuous Processing
As a next-gen CRDMO, driving global pharma with continuous, solvent-free tech for potent drug development BENGALURU, India, May 15, 2025 /PRNewswire/ -- STEERLife, the life sciences division of STEER World, is advancing the development and manufacturing of potent and complex drug products. This initiative marks a significant advancement in a field that has long been considered one of the most challenging areas within pharmaceutical science. At the core of this advancement is STEERLife's proprietary solvent-free melt fusion technology, a continuous processing system that eliminates the need for harmful organic solvents. Designed to precisely handle high-potency and hard-to-develop molecules, this platform significantly enhances formulation efficiency, safety, and scalability. As a next-generation Contract Research, Development & Manufacturing Organization (CRDMO), STEERLife provides comprehensive development capabilities for complex and potent drugs - including NCEs, hormone therapies, orphan drugs, complex generics (ANDAs) and 505(b)(2) products, assisting global pharma in overcoming development and manufacturing challenges through process-driven innovation. "Potent drug development demands more than just compliance; it requires control, care, and innovation," said Indu Bhushan, CEO & Director at STEERLife. "Our continuous, solvent-free platform brings all of that together - enabling faster, cleaner and more scalable development for the world's most demanding therapies." STEERLife has already initiated the development of several key drug products set for market release from 2026 onwards. These include generic versions of ERLEADA® (Apalutamide), XTANDI® (Enzalutamide), VENCLEXTA® (Venetoclax), and LYNPARZA® (Olaparib), reflecting the company's ability to take on complex, high-barrier drug programs with confidence. Working in tandem with partner facilities, STEERLife is strategically positioned to serve leading pharmaceutical markets across the United States, Europe, Latin America, Russia, MENA and Southeast Asia. As a company that pioneered the shift from batch to seamless continuous processing in India, STEERLife continues to lead the evolution of pharmaceutical manufacturing - empowering clients worldwide to shorten development timelines, raise quality benchmarks and unlock next-gen drug delivery. About STEERLife STEERLife, a division of STEER World, is a pioneering life sciences company transforming how pharmaceuticals are developed, manufactured, and consumed. Leveraging cutting-edge continuous processing and proprietary clean & green technologies, STEERLife enables faster, greener and more efficient drug development. The company offers a complete spectrum of services to global partners: ranging from formulation and analytical development to technology transfer, regulatory support and commercial-scale manufacturing. View original content: SOURCE STEERLife Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Standard
14-05-2025
- Business
- Business Standard
Sai Life Sciences jumps after stellar Q4 results
Sai Life Sciences jumped 4.61% to Rs 759 after the company's net profit surged 105% to Rs 170 crore on 16% increase in revenue fropm operations to Rs 1695 crore in Q4 March 2025 over Q4 March 2024. EBITDA jumped 42% year-on-year (YoY) to Rs 425 crore in Q4FY25. EBITDA margin improved to 25% in Q4 FY25, compared to 20% in Q4 FY24. Profit before tax rose 108% YoY to Rs 228 crore in Q4FY25. For the full year, net profit rose 57% to Rs 88 crore on 32% increase in revenue from operations to Rs 580 crore in the year ended March 2025 over the year ended March 2024. EBITDA rose 30% YoY to Rs 161 crore in FY25. EBITDA margin was unchaged at 28% in FY25. PBT climbed 56% YoY to Rs 119 crore in FY25. Krishna Kanumuri, managing director and CEO, Sai Life Sciences, said, "We are pleased to report a strong performance for FY25, ably supported by solid execution, capacity expansion, and deeper engagement with our customers. Our integrated CRDMO model continues to add value, helping us deliver seamless solutions across the drug development lifecycle to our global and biotech partners. One of the highlights of the year was the launch of our Peptide Research Centre, set up to meet the growing demand for complex peptide synthesis and conjugation. This investment marks another step forward in strengthening our capabilities to support next-generation therapeutics. We remain focused on investing in technology, infrastructure, and talent to stay aligned with the evolving needs of our clients. As we step into FY26, our priorities remain clear - to expand our capabilities, improve execution, and deliver lasting value to our stakeholders. Siva Chittor, director and chief financial officer, Sai Life Sciences added, "We are pleased to report a strong FY25 performance, driven by consistent momentum across our CDMO and CRO segments. Revenue grew by 16% and our EBITDA margin expanded to 25%, in line with our growth aspirations. Profit after tax grew by 105%, supported by stable finance costs and operating leverage. With the completion of our planned Rs 720 Cr debt repayment, we have significantly strengthened our balance sheet and expect lower interest costs starting FY26. Capex for the year stood at Rs 408 Cr, focused on enhancing our manufacturing footprint and expanding discovery capabilities. We remain committed to disciplined execution and prudent capital allocation as we continue to build on our growth momentum and deliver long-term value to stakeholders." Hyderabad-based Sai Life Sciences is a leading global contract research, development, and manufacturing organization (CRDMO) that partners with innovator pharmaceutical and biotech companies to accelerate the discovery, development, and commercialization of new medicines. The company offers integrated solutions spanning medicinal chemistry, process development, clinical and commercial manufacturing, and advanced technology platforms.
Associated Press
28-04-2025
- Business
- Associated Press
WuXi AppTec Q1 2025 Revenue, Profit Resume Double Digit Growth, Revenue Up 21.0% YoY, Adjusted Non-IFRS Net Profit Up 40.0% YoY; Backlog for Continuing Operations Up 47.1% YoY
SHANGHAI, April 28, 2025 /PRNewswire/ -- WuXi AppTec (stock code: / a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry, today announced financial results for the first quarter ending March 31, 2025 ('Reporting Period'): Management Comment Dr. Ge Li, Chairman and CEO of WuXi AppTec, said, 'Revenue and profit both resumed double-digit growth during the first quarter, and our backlog for Continuing Operations sustained rapid growth, as we maintained our laser focus on leveraging WuXi AppTec's unique CRDMO platform to expand delivery of enabling services across research, development and manufacturing.' 'The Company currently maintains its full-year guidance set at the beginning of the year. We expect revenue from Continuing Operations to grow 10-15% in 2025, and our adjusted non-IFRS net profit margin will further improve.' 'WuXi AppTec is dedicated to 'doing the right thing and doing it right', as our services drive long-term growth, improve the health of those in need and realize our vision that 'every drug can be made and every disease can be treated'.' Business Performance by Segments This release provides a summary of the results and does not intend to provide a complete statement relating to the Company, its securities, or any relevant matters herein that a recipient may need in order to evaluate the Company. For additional information, please refer to the WuXi AppTec 2025 First Quarterly Results Presentation and 2025 First Quarterly Report disclosed on the Company's official website, as well as the Company's disclosure documents and information on the Shanghai Stock Exchange, the Stock Exchange of Hong Kong Limited website. Investors are advised to exercise caution and be aware of the investment risks in trading Company shares. Net profit attributable to the owners of the Company is prepared in accordance with China Accounting Standards for Business Enterprises (CAS), in currency of RMB. Besides, all other financial information disclosed in this press release is prepared in accordance with the International Financial Reporting Standards Accounting Standards ('IFRSs'), in currency of RMB. The 2025 First Quarterly Report of the Company has not been audited. About WuXi AppTec As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec's integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the fourth consecutive year in 2024 and its open-access platform is enabling ~6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that 'every drug can be made and every disease can be treated.' Please visit: Forward-Looking Statements This press release may contain certain statements that are or may be forward looking, which can be recognized by the use of words such as 'expects', 'plans', 'will', 'estimates', 'projects', 'intends', or words of similar meaning. Such forward-looking statements are not historical facts, but instead are predictions about future events based on our beliefs, development strategy, business plan as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, our ability to meet timelines for the expansion of our service offerings or to reach the scale of our production capacity expansion plans, our ability to protect our clients' intellectual property, competition, unforeseeable change of international policy, the impact of emergencies and other force majeure. Our forward-looking statements do not constitute any profit forecast by our management nor a undertaking by WuXi AppTec Co., Ltd. ('WuXi AppTec' or the 'Company') to our investors. ACCORDINGLY, YOU ARE STRONGLY CAUTIONED THAT RELIANCE ON ANY FORWARD-LOOKING STATEMENTS INVOLVES KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this press release is as of the date of this press release and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement or information in this press release to reflect future events or circumstances, except as required under applicable law. Continuing Operations and Discontinued Operations In accordance with the IFRSs, the Company has classified the operations for which equity sale agreements were signed during the Reporting Period or the comparison year as discontinued operations ('Discontinued Operations'). The remaining operations of the Company will continue to be reported as continuing operations ('Continuing Operations'). Use of Non-IFRS and Adjusted Non-IFRS Financial Measures We provide non-IFRS gross profit and non-IFRS net profit attributable to the owners of the Company, which exclude share-based compensation expenses, issuance expenses of convertible bonds, foreign exchange related gains or losses, amortization of acquired intangible assets from merger and acquisition, gains or losses from impairment and disposal of non-financial assets, and gains or losses from divestiture and restructuring initiatives, etc. We also provide adjusted non-IFRS net profit attributable to the owners of the Company and earnings per share, which further exclude realized and unrealized gains or losses from our venture capital investments and joint ventures. Neither of the above is required by, or presented in accordance with IFRSs. We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing our core business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and non-operating items that we do not consider indicative of the performance of our core business. Such non-IFRS financial measures, the management of the Company believes, is widely accepted and adopted in the industry the Company is operating in. However, the presentation of these adjusted non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRSs. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRSs, or as being comparable to results reported or forecasted by other companies. View original content: SOURCE WuXi AppTec
